NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
September 12, 2006 • Volume 3 / Number 35 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Genome Survey Links Many Genes to Breast, Colon Cancers

Director's Update
Unique Program Fosters Technology Development

Cancer Research Highlights
Paclitaxel Fails as Ongoing Treatment for Metastatic Breast Cancer

New Treatment Pays Dividends in Pediatric Medulloblastoma

70-Gene Signature for Breast Cancer Risk Validated

ERCC1 Expression in Lung Cancer May Predict Survival Benefit from Cisplatin

Intervention Increases Mammography Rates Among Triracial Women

Spotlight
Report to the Nation: U.S. Latinos and Cancer

Funding Opportunities

Featured Clinical Trial
Treating Malignant Peripheral Nerve Sheath Tumors

Notes
Office of Liaison Activities Redesigns Web Site

Presidential Proclamations for Cancer Awareness in September

Conference on Interleukin-15 Scheduled for October

"Understanding NCI" Teleconference Slated This Month

Community Update
Cancer Center Directors Report on Accelerating Successes Against Cancer

Bulletin Archive

About the Bulletin

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Genome Survey Links Many Genes to Breast, Colon Cancers

Last week, researchers reported the results of the first attempt to identify the genetic alterations involved in two common cancers using the tools developed to sequence the human genome.

They identified 189 mutated genes in tumors from patients with breast or colon cancers. The vast majority of genes had not been linked to cancer previously.

The team, led by researchers at the Johns Hopkins Kimmel Cancer Center, analyzed 13,000 genes in 11 colon tumors and 11 breast tumors. Each tumor had 90 genetic mutations on average, of which 11 to 17 mutations may have been critical in causing cancer.  Read more  



Director's Update

Unique Program Fosters Technology Development

Last week, more than 100 NCI-sponsored investigators met in Bethesda, Md., to discuss their projects and share ideas about the best ways to develop the technologies of the future. With just a glance at the agenda, you can see that this 2-day session echoed many of the exciting themes of today's cancer research: biomarkers, proteomics, signal transduction pathways, cellular imaging, and identification of cancer stem cells.

It is becoming clearer every day that technology development will both integrate and drive the chemical, physical, and biological sciences. NCI's Innovative Molecular Analysis Technologies (IMAT) program, which hosted last week's event, is aimed squarely at devising and developing novel and emerging technologies in the support of cancer research, treatment, diagnosis, and prevention. In other words, technology is fueling the engines of discovery and translation.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov